A3160
乙酰水杨酸
analytical standard
别名:
2-乙酰氧基苯甲酸, O-乙酰水杨酸, ASA, 阿司匹林
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
2-(CH3CO2)C6H4CO2H
化学文摘社编号:
分子量:
180.16
UNSPSC Code:
12352106
NACRES:
NA.21
PubChem Substance ID:
EC Number:
200-064-1
Beilstein/REAXYS Number:
779271
MDL number:
产品名称
乙酰水杨酸, analytical standard
InChI key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
SMILES string
CC(=O)Oc1ccccc1C(O)=O
grade
analytical standard
form
powder
packaging
vial of 500 mg
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
mp
134-136 °C (lit.)
application(s)
forensics and toxicology
pharmaceutical
veterinary
Quality Level
Gene Information
human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
通过抑制环氧化酶(前列腺素H合酶)，对COX-1亚型具有更高的选择性，阻止前列腺素的产生。抗血栓作用是由于COX-1在血小板中的抑制作用，阻止血栓形成和血小板聚集。 对结直肠及其他实体肿瘤有化学预防作用。
Packaging
棕色螺纹盖样品瓶包装
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
482.0 °F
flash_point_c
250 °C
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持